» Articles » PMID: 19944367

Incremental Prognostic Values of Serum Tenascin-C Levels with Blood B-type Natriuretic Peptide Testing at Discharge in Patients with Dilated Cardiomyopathy and Decompensated Heart Failure

Overview
Journal J Card Fail
Date 2009 Dec 1
PMID 19944367
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study investigates the predictive value of serum tenascin-C (TN-C), which is observed at the active sites of ongoing tissue remodeling, for cardiac events of patients with dilated cardiomyopathy (DCM).

Methods And Results: In this trial, 110 consecutive patients hospitalized with heart failure (HF) resulting from DCM underwent assessments of serum TN-C and plasma brain natriuretic peptide (BNP) levels at discharge and were followed up for 22.4 months. Cardiac function and hemodynamics were assessed invasively in 60 of these patients at discharge. There were 19 cardiac events (14 rehospitalizations, 3 deaths from refractory HF, and 2 sudden deaths) during follow-up. The average levels of TN-C and BNP were 73 +/- 38 ng/mL and 279 +/- 414 pg/mL, respectively. The optimal cutoff value for serum TN-C levels predicted cardiac events were >or=78.4 ng/mL, whereas BNP levels were >or=219 pg/mL. Patients with levels higher than this had significantly higher cardiac events and serum TN-C >or=78.4 ng/mL had an incremental predictive power with BNP for cardiac events. Left ventricular end-diastolic volume was significantly larger, and mean pulmonary arterial pressure was elevated in patients with serum TN-C >or=78.4 ng/mL.

Conclusions: The combined index of serum levels for TN-C and BNP at discharge predicts cardiac events from decompensated HF. Additionally, elevated serum TN-C levels reflect left ventricular and pulmonary vascular remodeling in DCM patients.

Citing Articles

Biology of Tenascin C and its Role in Physiology and Pathology.

Abedsaeidi M, Hojjati F, Tavassoli A, Sahebkar A Curr Med Chem. 2023; 31(19):2706-2731.

PMID: 37021423 DOI: 10.2174/0929867330666230404124229.


Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.

Yoshikane Y, Okuma Y, Miyamoto T, Hashimoto J, Fukazawa R, Kato T Pediatr Rheumatol Online J. 2021; 19(1):82.

PMID: 34090475 PMC: 8180154. DOI: 10.1186/s12969-021-00562-w.


Tenascin-C in Heart Diseases-The Role of Inflammation.

Imanaka-Yoshida K Int J Mol Sci. 2021; 22(11).

PMID: 34072423 PMC: 8198581. DOI: 10.3390/ijms22115828.


Immunomodulatory Role of Tenascin-C in Myocarditis and Inflammatory Cardiomyopathy.

Tajiri K, Yonebayashi S, Li S, Ieda M Front Immunol. 2021; 12:624703.

PMID: 33692798 PMC: 7938317. DOI: 10.3389/fimmu.2021.624703.


The Roles of Tenascins in Cardiovascular, Inflammatory, and Heritable Connective Tissue Diseases.

Matsumoto K, Aoki H Front Immunol. 2020; 11:609752.

PMID: 33335533 PMC: 7736112. DOI: 10.3389/fimmu.2020.609752.